RxDoctor Payments Data

Ioana Bonta, MD

Hematology & Oncology · Atlanta, GANPI 1306090659

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Johnson & Johnson at 29.6% of the total. 2025 is the largest year on record at $43,122, 6.0 times the $7,211 reported in 2019. Among hematology & oncology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,381in general payments, 2019–2025

Across 300 payments — averaging $237.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$21K
  • AstraZeneca$9K
  • Novartis$8K
  • Regeneron$6K
  • Jazz Pharmaceuticals Inc.$5K
  • Bayer$5K
  • plus $17K from 51 others
$685,956in research payments, 2019–2025

Across 83 payments — averaging $8264.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$344K
  • Merck$179K
  • G1 Therapeutics, Inc.$66K
  • Astellas Pharma Global Development$62K
  • AstraZeneca$35K

What the payments were for

  • Consulting fees$40,93757%
  • Speaking & faculty fees$22,71532%
  • Travel & lodging$1,3622%
  • Food & beverage$6,3029%
  • Education$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,381 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$47,334
Medicare patients
194
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide15$311,776
CalquenceAcalabrutinib Maleate12$163,099
XareltoRivaroxaban11$7,994
EliquisApixaban11$7,568
CholestyramineCholestyramine (With Sugar)11$879
Ondansetron OdtOndansetron35$804
Anastrozole21$348
Pantoprazole Sodium19$321
Prochlorperazine Maleate14$314
Dexamethasone21$271
Sodium Chloride0.9 % Sodium Chloride15$237
Letrozole11$201
Levothyroxine Sodium16$184
Mirtazapine18$171
Gabapentin13$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$247$311,77615 claims
AstraZenecaCalquence$9,372$163,09912 claims
Johnson & JohnsonXarelto$21,160$7,99411 claims
PfizerEliquis$550$7,56811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →